The splicing factor ESRP1 regulates CD44 splice switching during the epithelial-mesenchymal transition15, and SF3B2 drives prostate cancer progression through AS of androgen receptor (AR) to increase AR-V7 expression16. Here, AR is linked to prostate carcinoma.